Global Health News: Lancet's Senate Rejection, Opioid Crisis Developments, and Innovation in Medical Coverage

This update summarizes key health news, including The Lancet's refusal to testify in a US Senate COVID-19 origins inquiry, Purdue Pharma's sentence delay for opioid charges, and advances in US health regulations. Other topics include UK data privacy inquiries, innovations in Medicare device coverage, and changes in pharmaceutical sales strategies.

The Lancet, a prominent medical journal, has decided not to cooperate with a US Senate inquiry into the origins of the COVID-19 pandemic, signifying a bold stance against political pressures. Editor-in-chief Richard Horton confirmed this decision during the Reuters Pharma event in Barcelona.

In another development, Purdue Pharma's criminal sentencing related to opioid marketing has been postponed to allow for increased public input. US District Judge Madeline Cox Arleo delayed the hearing, originally set for this week in Newark, New Jersey, where Purdue faced a $3.5 billion criminal fine and a $2 billion forfeiture penalty.

Meanwhile, US health regulators have announced plans to accelerate Medicare coverage for medical devices, reducing approval and reimbursement timelines. This shift aims to boost innovation and investment by addressing longstanding concerns over regulatory delays that have hindered the medical technology sector.